DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?

Affiliations

¹ Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China; Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China; Clinical Oncology Centre, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China. Electronic address: lamkaon@hku.hk.
² Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China.
³ Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China; Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China; Clinical Oncology Centre, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
⁴ Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.

Comment

Ka On Lam et al. Lancet Oncol. 2019 Feb.

. 2019 Feb;20(2):e66.

doi: 10.1016/S1470-2045(18)30867-2.

¹ Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China; Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China; Clinical Oncology Centre, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China. Electronic address: lamkaon@hku.hk.
² Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China.
³ Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China; Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China; Clinical Oncology Centre, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
⁴ Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.

No abstract available

Comment in

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.
Henricks LM, Lunenburg CATC, Cats A, Mathijssen RHJ, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Lancet Oncol. 2019 Feb;20(2):e67. doi: 10.1016/S1470-2045(19)30010-5. Lancet Oncol. 2019. PMID: 30712800 No abstract available.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537